200,000+ products from a single source!
sales@angenechem.com
269718-83-4 | 2(3H)-BENZOXAZOLONE, 7-(4-METHYL-1-PIPERAZINYL)-, MONOHYDROCHLORIDE
CAS No: 269718-83-4 Catalog No: AG00BF6E MDL No:
Product Description
Catalog Number:
AG00BF6E
Chemical Name:
2(3H)-BENZOXAZOLONE, 7-(4-METHYL-1-PIPERAZINYL)-, MONOHYDROCHLORIDE
CAS Number:
269718-83-4
IUPAC Name:
7-(4-methylpiperazin-1-yl)-3H-1,3-benzoxazol-2-one;hydrochloride
InChI:
InChI=1S/C12H15N3O2.ClH/c1-14-5-7-15(8-6-14)10-4-2-3-9-11(10)17-12(16)13-9;/h2-4H,5-8H2,1H3,(H,13,16);1H
InChI Key:
NQRIKTDKFHAOKC-UHFFFAOYSA-N
UNII:
U40903X6V8
Properties
Complexity:
302
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
269.093g/mol
Formal Charge:
0
Heavy Atom Count:
18
Hydrogen Bond Acceptor Count:
4
Hydrogen Bond Donor Count:
2
Isotope Atom Count:
0
Molecular Weight:
269.729g/mol
Monoisotopic Mass:
269.093g/mol
Rotatable Bond Count:
1
Topological Polar Surface Area:
44.8A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
| Title | Journal |
|---|---|
| Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. | Parkinsonism & related disorders 20120501 |
| Temporal stability of the Unified Dyskinesia Rating Scale. | Movement disorders : official journal of the Movement Disorder Society 20111201 |
| In vivo effects of pardoprunox (SLV308), a partial D₂/D₃ receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity. | Synapse (New York, N.Y.) 20111001 |
| Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile. | Journal of medicinal chemistry 20110714 |
| Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. | Movement disorders : official journal of the Movement Disorder Society 20110701 |
| The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets. | Experimental neurology 20101201 |
| Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets. | Movement disorders : official journal of the Movement Disorder Society 20101015 |
| An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20100801 |
| Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. | Movement disorders : official journal of the Movement Disorder Society 20100430 |
| Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease. | European neurology 20090101 |
| In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist. | Synapse (New York, N.Y.) 20061215 |
| SLV-308. Solvay. | Current opinion in investigational drugs (London, England : 2000) 20030701 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.